JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
News Oct 10, 2015
Debiopharm Group™ will be presenting the ‘JCA-Mauvernay Award’ on October 10 to Doctors Yutaka Kondo from the Nagoya City University Graduate School of Medical Sciences for his basic research on Targeting Epigenetics as a New Paradigm in Cancer Treatment and Junko Takita from Graduate School of Medicine, the University of Tokyo for her applied research on Identification of Molecular Therapeutic Targets for Pediatric Cancers.
Doctors Kondo and Takita will receive their Awards during the General Assembly of the 74th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya City on the following theme: ‘From collaboration to integration: Cancer research for patients’ benefit’. Dr. Kohei Miyazano, President of the JCA and Thierry Mauvernay, Delegate of the Board of Debiopharm Group, will present the trophies to both scientists.
“We are honored and proud to reward such talented scientists chosen for the high standard and potential applications of their research. We wish them both success with their work and hope they will lead to effective treatments in the years to come”, said Thierry Mauvernay, Delegate of the Board of Debiopharm Group.
Dr. Kondo explores the role of epigenetic dysregulation in cancer. Differences in tumor behavior can be explained by variations in gene expression patterns, which can be generated by epigenetic mechanisms. His research focuses on the functional impact of aberrant epigenetic mechanisms on tumorigenesis, and their potential clinical application in areas such as cancer detection, classification and therapeutic targets validation.
One of the significant causes of death among children is pediatric cancers. Dr. Takita and her group have conducted extensive studies on the molecular mechanisms of intractable pediatric cancers, including neuroblastoma, rhabdomyosarcoma, pleuropulmonary blastoma and hematological malignancies. Their recent studies have shown the differences in the molecular mechanisms underlying pediatric and adult leukemias.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018